Chinese Medical Sciences Journal ›› 2018, Vol. 33 ›› Issue (3): 183-187.doi: 10.24920/31805

• 病例报告 • 上一篇    下一篇



  1. 1 青岛大学附属中心医院肿瘤科,青岛,266062
    2 青岛市肿瘤医院肿瘤科,青岛,266042
  • 出版日期:2018-09-30 发布日期:2018-07-16
  • 通讯作者: 季有信

Treatment of Skin Reaction Induced by Nivolumab Combined with Radiotherapy in Non-small Cell Lung Cancer: A Case Report

Zhao Zhimei1,Liu Shichao2,Xu Xiajuan1,Zhang Zhongfa2,Nie Keke2,Ji Youxin1,*()   

  1. 1 Department of Oncology, Affiliated Qingdao Central Hospital of Qingdao University, Qingdao, Shandong 266042, China
    2 Department of Oncology, Qingdao Cancer Hospital, Qingdao, Shandong 266042, China
  • Published:2018-09-30 Online:2018-07-16
  • Contact: Ji Youxin



关键词: 皮肤反应, 纳武单抗, 免疫治疗, 放射治疗, 非小细胞肺癌


Skin reaction or dermatological toxicities induced by immunotherapy is common. It usually manifests skin rash or erythema and can be cured by skin lotion or steroid. Nivolumab, a human IgG4 programmed cell death protein 1 (PD-1) inhibitor, blocks T cells activation preventing signal and allows the immune system to clear cancer cells. Nivolumab was approved in the second-line therapy in squamous cell lung cancer by FDA, with less than 10% unusual skin reaction, like sensory neuropathy, peeling skin, erythema multiforme, vitiligo, and psoriasis. Radiotherapy could aggravate this skin reaction through inflammatory response and promotion of immunity. The combined treatment of anti-PD-1 and radiotherapy represented a new promising therapeutic approach in many studies, but the risk of side effects may be high. We reported a patient with advanced squamous cell lung cancer who suffered from serious skin immune-related adverse events when he was treated with nivolumab and radiotherapy. The immune overreaction of the treatment of anti-PD-1 treatment and radiotherapy might cause these serious skin adverse events. Our report warranted careful workup to reduce the risk of side effects by combinative therapy with anti-PD-1 and radiotherapy.

Key words: skin reaction, nivolumab, immunotherapy, radiotherapy, non-small cell lung cancer

Copyright © 2018 Chinese Academy of Medical Sciences. All right reserved.
京公安备110402430088 京ICP备06002729号-1  Powered by Magtech.

Supervised by National Health Commission of the People's Republic of China

9 Dongdan Santiao, Dongcheng district, Beijing, 100730 China

Tel: 86-10-65105897  Fax:86-10-65133074 


Copyright © 2018 Chinese Academy of Medical Sciences

All right reserved.

京公安备110402430088  京ICP备06002729号-1